Drug intelligence / Profile preview

sodium chlorate

Development stage: Unknown
Lead developer: Apotex
Modality: Small Molecules
Administration: Intravenous

Overview

NRI-1026 is the internal research designation for sodium chlorate, a small-molecule inorganic salt developed by Nuvo Research GmbH (a subsidiary of Nuvo Research Inc.). It is one of the two primary active constituents of WF10, an investigational intravenous immunomodulator. NRI-1026 has been evaluated in Phase 1/2 clinical trials in Germany for the treatment of refractory allergic rhinitis. The compound is believed to contribute to the overall immunomodulatory profile of WF10, which involves the regulation of macrophage activity and inflammatory cytokine production, although the specific molecular target of NRI-1026 as a standalone agent is not publicly detailed.

Other names: sodium chlorate

Beyond the preview

Go deeper on sodium chlorate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sodium chlorate.

Explore the full profile